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Abstract: Introduction: Schizophrenia is a severe psychiatric disorder, with executive dysfunction and
impaired processing speed playing a pivotal role in the course of the disease. In patients with schizophre-
nia, neurocognitive deficits appear to be related to alterations in cerebral hemodynamics. It is not fully
understood if psychopathological symptom load (i.e., presence and severity of symptoms) is also related
to alterations in cerebral hemodynamics. We aim to study the relationship between psychopathological
symptom load and cerebral hemodynamics in the Middle Cerebral Artery (MCA) during a cognitive task
in patients with schizophrenia and healthy controls. Methodology: Cerebral hemodynamics in the MCA
were examined in 30 patients with schizophrenia and 15 healthy controls using functional Transcranial
Doppler (fTCD) during the Trail Making Test (TMT). Psychopathological symptoms were measured
using the Brief Psychiatric Rating Scale (BPRS). Patients were dichotomized according to BPRS scores:
mild-moderate (BPRS < 41, n = 15) or marked-severe (BPRS ฀ 41, n = 15). Mean blood flow velocity
(MFV) in the MCA and processing speed of the TMT were analyzed. Cerebral hemodynamics were
analyzed using the general additional model (GAM) with a covariate analysis of variance (ANCOVA)
for group comparisons. Results: Patients and healthy controls were comparable regarding demographics.
Patients had a slower processing speed for the TMT-A (patients-severe: 52s, patients-moderate: 40s,
healthy-controls: 32s, p = 0.019) and TMT-B [patients-severe: 111s, patients-moderate: 76s, healthy-
controls: 66s, p < 0.001)]. Patients demonstrated differing hemodynamic profiles in both TMTs: TMT-
A [F (6,1,792) = 17, p < 0.000); TMT-B [F (6,2,692) = 61.93, p < 0.000], with a delay in increase in MFV
and a failure to return to baseline values. Conclusions: Patients with schizophrenia demonstrated slower
speeds of processing during both the TMT-A and TMT-B. The speed of processing deteriorated with
increasing psychopathological symptom load, additionally a distinct cerebral hemodynamic pattern in
the MCA was observed. Our results further support the view that severity of schizophrenia, particu-
larly psychopathological symptom load, influences performance in neurocognitive tasks and is related to
distinct patterns of brain hemodynamics.
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Introduction: Schizophrenia is a severe psychiatric disorder, with executive dysfunction
and impaired processing speed playing a pivotal role in the course of the disease. In
patients with schizophrenia, neurocognitive deficits appear to be related to alterations
in cerebral hemodynamics. It is not fully understood if psychopathological symptom
load (i.e., presence and severity of symptoms) is also related to alterations in cerebral
hemodynamics. We aim to study the relationship between psychopathological symptom
load and cerebral hemodynamics in the Middle Cerebral Artery (MCA) during a cognitive
task in patients with schizophrenia and healthy controls.
Methodology: Cerebral hemodynamics in the MCA were examined in 30 patients with
schizophrenia and 15 healthy controls using functional Transcranial Doppler (fTCD) during
the Trail Making Test (TMT). Psychopathological symptoms were measured using the
Brief Psychiatric Rating Scale (BPRS). Patients were dichotomized according to BPRS
scores: mild-moderate (BPRS < 41, n = 15) or marked-severe (BPRS ≧ 41, n = 15).
Mean blood flow velocity (MFV) in the MCA and processing speed of the TMT were
analyzed. Cerebral hemodynamics were analyzed using the general additional model
(GAM) with a covariate analysis of variance (ANCOVA) for group comparisons.
Results: Patients and healthy controls were comparable regarding demographics.
Patients had a slower processing speed for the TMT-A (patients-severe:
52s, patients-moderate: 40s, healthy-controls: 32s, p = 0.019) and TMT-B
[patients-severe: 111s, patients-moderate: 76s, healthy-controls: 66s, p < 0.001)].
Patients demonstrated differing hemodynamic profiles in both TMTs: TMT- A [F (6, 1,792)
= 17, p < 0.000); TMT-B [F (6, 2,692) = 61.93, p < 0.000], with a delay in increase in MFV
and a failure to return to baseline values.
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Conclusions: Patients with schizophrenia demonstrated slower speeds of processing
during both the TMT-A and TMT-B. The speed of processing deteriorated with increasing
psychopathological symptom load, additionally a distinct cerebral hemodynamic pattern
in the MCA was observed. Our results further support the view that severity of
schizophrenia, particularly psychopathological symptom load, influences performance
in neurocognitive tasks and is related to distinct patterns of brain hemodynamics.
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INTRODUCTION
Schizophrenia is a severe psychiatric disorder which is
characterized by hallucinations, delusions and blunted affect
(1). Although not part of the diagnostic criteria, cognitive
impairment is also a common feature of schizophrenia, often
occurring before the onset of the first psychotic episode
and continuing throughout the course of the disease (2, 3),
with cognitive impairment and executive functions playing a
pivotal role for outcome and prognosis, as well as being major
determinants of quality of life and well-being (4, 5).
Cognitive impairment and executive function are measured
by numerous neuropsychological assessment tools, including the
Trail Making Test (TMT)-A and TMT-B. In contrast to other
neuropsychological instruments, the TMTs are easy to use; their
interpretation is straightforward. Consequently, they are widely
used in both research and clinical practice (6, 7). The TMTs are
considered to be sensitive to cognitive dysfunction and frontal
lobe integrity, assessing graphomotor activity, visual scanning,
selective attention, mental flexibility and executive functioning
(6, 7). Patients with schizophrenia show impaired performance
in the TMT, with deficits in processing speed and inefficient
simultaneous processing strategies (6, 8). There is evidence that
in patients with schizophrenia, the frontal lobes, particularly the
dorsolateral prefrontal cortex (DLPFC), play a pivotal role in
executing the TMTs (9, 10).
Cognitive performance is partly determined by the brain’s
ability to increase blood supply to the areas activated during
a cognitive task. Due to the skull’s anatomic conditions, the
increase in diameter of the cerebral arteries is limited; an increase
in cerebral blood supply is achieved by increasing blood flow
velocity in the cerebral arteries. Therefore, we consider Mean
Flow Velocity (MFV) a valid indicator for brain activity (11, 12).
Transcranial Doppler (TCD) is a versatile, non-invasive method
for assessing the cerebral arteries’ functioning and hemodynamic
characteristics (11, 13). TCDprovides a continuousmeasurement
of blood flow velocity with high temporal resolution. However,
TCD has low anatomical resolution and is not able to deliver
a direct brain image. Despite this limitation, TCD has been
used to study physiological and hemodynamic conditions in
several neurological diseases and psychiatric disorders (11, 13,
14). The neurocognitive impairment in schizophrenia appears
to be related to alterations in blood flow in several brain areas,
including the DLPFC (15–18).
The middle cerebral arteries (MCA) irrigate the brain’s lateral
hemispheres, including the DLPFC, subcortical structures, basal
ganglia and the striatum (19). A number of these structures,
principally the DLPFC, striatum and thalamus, are activated
during the TMT (17), making fTCD a suitable method for the
physiological and hemodynamic assessment of brain activity in
these areas during a neurocognitive task (20). Previous studies
using functional TCD (fTCD) in patients with schizophrenia
and healthy controls showed clear differences in the MCA
hemodynamic pattern during the TMT (14); to what extent
there are also hemodynamic differences between those affected
with schizophrenia, in relation to the number and severity of
symptoms (i.e., symptom load) is thus far unexplored.
Our study aims to determine the relationship between
psychopathological symptom load (in healthy controls and
patients with schizophrenia) and cerebral hemodynamics in
the MCA during a neurocognitive task. New results may
contribute to increased use of fTCD as an assessment tool
in neuropsychiatric disorders, particularly schizophrenia. We
examined cerebral blood flow velocity during the TMT in
patients with schizophrenia and healthy controls, using a
visuomotor control task to compensate for hemodynamic




Thirty patients fulfilling the WHO-ICD 10 (21) criteria for
schizophrenia participated in this study; they were age and
sex-matched with 15 healthy controls. The healthy controls
had no medical, neurological or psychiatric condition at the
time of examination; they were recruited for a previous study
conducted by our research group, using the same examination
protocol and equipment (14). All participants were right-handed.
All patients with schizophrenia were taking antipsychotic
medication. The following exclusion criteria applied to patients:
1. affective disorder (according to ICD-10: F3); 2. organic brain
disorder (according to ICD-10: F0); 3. active substance abuse
disorder (according to ICD-10: F1) in the 3 months before
inclusion; 4. unstable neurological; or 5. medical condition. Basic
demographic characteristics of the participants were collected.
Besides the participants’ education, we included the mean
education of their parents to disentangle poor educational
performance attributable to early onset of the disorder or familial
accumulation. The competent ethics committee approved the
study, all participants provided written informed consent.
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Clinical Assessment and Psychometric
Measurements
Within 24 h of the fTCD measurement, psychopathological
symptoms were assessed using the Brief Psychiatric Rating
Scale (BPRS) (22), overall clinical severity of symptoms was
assessed using the Clinical Global Impression Scale (CGI) (23).
For this study, the daily antipsychotic dose was converted to
chlorpromazine equivalents according to current guidelines (24,
25). Effects of antipsychotics on the extrapyramidal system were
examined using the Simpson- Angus Scale (SAS) (26) and the
Barnes Akathisia Scale (BAS) (27, 28).
The BPRS is one of the most frequently used scales to measure
psychopathology in patients with schizophrenia, systematically
assessing the presence and severity of symptoms. It consists
of 18 single items assessing different symptoms. Each item is
evaluated according to a seven-item Likert scale, ranging from
“1” (not present) to “7” (extremely severe). Thus, the sum score
ranges from 18 to 126. We used the BPRS sum score as a
measure of the psychopathological symptom load. Participants
were classified according to BPRS sum scores, as “non-affected”
or healthy controls; those with a diagnosis of schizophrenia and
a BPRS score below 41 points were classified as “mild-moderate,”
those with a BPRS score of 41 points or more were classified as
“marked- severe”(29).
Equipment and Cerebral Blood Flow
Measurements
Doppler measurements were performed using a Multi-Dop X
instrument (DWL Elektronische Systeme GmbH, Sipplingen-
Germany). Two dual 2 MHz transducers were attached and
fixed with a headband. Both MCAs were insonated at depths
of 48–55mm through the temporal bone window. The 2 MHz
transducers were fixed with a headband, so motion artifacts of
the head did not alter the position of the transducers. This
approach is supported by published evidence demonstrating that
functional transcranial Doppler is fairly robust to movement
artifacts (30). As indicated by measurement artifact data, we
screened for MFV values outside the 60–150% range of the
mean MFV recording of a subject before, after and during the
cognitive task.
Cerebral Hemodynamics and Cognitive
Task
Subjects were asked to abstain from caffeine and nicotine
consumption 2 h prior to the examination (31). MFV data
were continuously recorded during the psychological paradigm,
integrating MFV data for each cardiac cycle. Participants
underwent a standardized briefing. They were instructed about
the nature of the study and the psychological paradigm. To
reduce learning effects, the cognitive task was presented only
once.We administered the TMTs as a paper and pencil test. In the
TMT-A, subjects had to connect 25 numbers in ascending order
(i.e., 1, 2, 3,..., 25). In the TMT-B, participants had to connect
numbers (1–13) and letters (A–L) alternately in ascending order
(i.e., 1, A, 2, B, 3, C,..., 13, L). Subjects had to solve the TMTs as
quickly and accurately as possible. In the control task participants
were asked to randomly connect circles placed in a 10 by
10 cm square. Lines had to be drawn at a pace of 1.0 or 0.5Hz
to simulate the pace of the TMT-A (0.89+−0.21Hz) and the
TMT-B (0.46+−0.15Hz). The control task simulates visuomotor
scanning during the TMTs. The control task was placed randomly
before or after each TMT, with a break of 60 s between each task.
Statistical Analysis
Data are presented in tables using simple descriptive statistics
(mean, standard deviation, percentages). For the analysis of
group differences, specific statistical tests were performed.
Continuous data were analyzed using a univariate analysis of
variance (ANOVA), with a secondary t-test to evaluate model
differences. The chi-square test was applied to categorical data. A
post hoc power analysis was conducted, using the effect sizes for
differences in completion time between the TMT-A and TMT-B.
For the purposes of analysis, the MFV consisted of the
following elements, following procedures used in a previous
study (20): (a). integration ofMFV from 100Hz sampling to 1Hz;
(b). normalization of digitized data with reference to pre-and
post-task rest phases (60s intervals of rest with 30s between the
first and last 15s); and (c) relative MFV (relative to resting state)
values, averaged and converted to percentage values. All MFV
values in this paper are relative MFV, i.e., cerebral blood flow
velocity change compared with resting phase values. For analysis
of the TMT-A and B, the time to be analyzed was dictated by the
time required by the fastest participant to complete the task.
The general additional model (GAM); was used for graphical
representation, as well as to statistically evaluate the change in
mean flow velocity over time (in seconds), controlled for side
and sex. The advantage of non-parametric tests, such as the
general additional model, lies in their greater flexibility regarding
assumptions about data (32–34). The GAM allows for regression
and weight analysis at both fixed and random variable level
(or for discrete and continuous variables) (33). Using a non-
parametric test allows for a realistic visual comparison of flow
velocity, facilitating the inference of its clinical relevance (35,
36). Accordingly, a better representation of dynamic and inter-
dependent results such as blood flow is provided. However,
the mathematical and statistical analysis and consequently,
comparison of the GAMs outcomes is more complex (34, 37).
Therefore, a covariate analysis of variance (ANCOVA) was used
to evaluate differences in the GAM of blood flow velocity
obtained for each group and side. Thus, allowing us to determine
whether a statistical difference between the hemodynamic curves
was demonstrated., A pairwise-comparison was conducted to
determine the time frames in which the curves differed from
one another.
RESULTS
Demographics and Clinical Characteristics
Patients and control subjects were comparable regarding age,
sex and years of parent’s education. Years of own education
for those with schizophrenia was significantly shorter than
healthy controls, with no difference between severity groups.
Patients with a marked-severe psychopathological symptom
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load obtained significantly higher CGI-S scores than those
with moderate symptomatology [3.60 ± 1.06 vs. 5.20 ± 0.68,
F(1, 28) = 24.44, p < 0.001]. The duration of illness and
hospitalization rates did not differ significantly between patient
groups. Each participant with a diagnosis of schizophrenia had
an antipsychotic prescribed, some two. Most antipsychotics
prescribed were second-generation antipsychotics. There were
no significant differences regarding the antipsychotics prescribed
(data not shown) and dose (as chlorpromazine equivalents).
Furthermore, the rate of extrapyramidal motor symptoms and
akathisia was also similar (see Table 1). The post hoc power
analysis reached a power of 1-ß of 0.99.
TMT Performance
In comparison to healthy controls, patients with schizophrenia
required significantly more time to complete both TMTs.
Furthermore, more severely ill patients took significantly longer
to complete the test than those classified as mild-moderately ill;
TMT-A [patients-severe: 52.3 ± 30.8; patients-moderate: 40.2 ±
12.7; healthy-controls: 31.0 ± 7.4, F(2, 42) = 4.38, p = 0.019] and
TMT-B [patients-severe: 66.2 ± 18.9; patients-moderate: 75.5
± 22.9; healthy-controls: 111.1 ± 20.9, F(2, 42) = 19.08, p <
0.001]. Since the fastest performance on the TMT-A was 20s,
and for the TMT-B 30s, these are the time periods considered for
statistical analysis. There was no statistically significant difference
between groups regarding the rate of errors on the TMTs
(see Table 1).
Mean Cerebral Blood Flow Velocity During
the TMT-A
For healthy-controls, there was a significant change in MFV over
time [F(s)(3.991, 4.912) = 15.43, p < 0.001], with a hemispheric
difference in MFV [F(1, 266) = 10.55, p = 001]; in the post
hoc pairwise analysis we identified that the hemispheric (right
> left) difference was only significant for the first 10 s of the
measurement period. For those mildly-moderately affected, there
was also a change of MFV over time [F(s)(7.403, 8.356) = 6.707, p
< 0.001], we did not find a hemispheric difference in the MFV
[F(1, 266) = 0.979, p = 0.323]; with the post hoc pairwise analysis
also demonstrating no hemispheric differences at any time
point. Finally, in those with higher psychopathological symptom
load, we found a change in MFV over time [F(s)(8.087, 8.767)
= 9.746, P < 0.001], with a hemispheric difference (left >
right) in the MFV [F(1, 266) = 7.71, p < 0.001]; the post
hoc pairwise comparison indicating that this difference was
only significant during the middle phase of the measurement
(s 9 to 14). There is a statistically significant difference
between the curves of the three groups under comparison
[F(6, 1,792) = 17, p < 0.000].
Group differences and hemispheric differences inMFV during
the TMT-A are graphically represented (Figure 1). The mean
flow velocity in both middle cerebral arteries shows a similar
pattern for all three groups during the TMT-A; in the first 5–
10 s, there is an increase in blood flow followed by a steady
decrease. Healthy controls reached the peak of blood flow 2 s
faster than those with schizophrenia. Furthermore, those with
marked-severe psychopathological symptom load show a delayed
and higher increase and a slighter decrease in the blood blow
velocity in the left MCA.
Mean Cerebral Blood Flow Velocity During
the TMT-B
Healthy controls demonstrate a change of MFV over time
[F(s)(4.890, 5.952) = 23.04, p < 0.001], without a hemispheric
difference in MFV [F(1, 406) = 0.693, p = 0.405] during the
TMT-B. Those mild-moderately affected also showed a change
in MFV over time [F(s)(8.106, 8.779) = 18.62, p < 0.001], without
a hemispheric difference in MFV [F(1, 406) = 1.117, p = 0.291],
the post hoc pairwise comparison, however, demonstrated a
difference for the first eight s of the measurement period.
Those more severely affected also demonstrated a change in
MFV over time [F(s)(5.750, 6.882) = 3.888, p < 0.001], and a
hemispheric difference in MFV [F(1, 406) = 28.42, p < 0.001];
with the pairwise post hoc comparison revealing a significant
difference for the first 5 s and in the middle phase of the
measurement period (s 18 to 21). There is a statistically
significant difference between the curves of the three comparison
groups [F(6, 2,692) = 61.93, p < 0.000).
Group differences and hemispheric differences inMFV during
the TMT-B are graphically represented (Figure 2). Healthy
controls reach a peak in blood flow after 5 s, with a continuous
decrease. Those with mild-moderate psychopathological
symptom load also reach the first peak after 7 s, followed by a
slight decrease and a second lower peak. Finally, those with more
severe schizophrenia show a discrepancy between both MCAs.
Both MCAs form two peaks, the first just a few seconds after
beginning the task, the second after 20 s. The right MCA shows
a lower increased MFV, demonstrating a lower initial peak than
the left MCA 20 s after beginning the task.
DISCUSSION
Using an age and gender-balanced sample population,
including patients with schizophrenia and healthy controls,
we examined the mean blood flow velocity during the TMT-A
and TMT-B in the middle cerebral artery using functional
transcranial doppler. In our study, participants with a higher
psychopathological symptom load (represented by higher BPRS
scores) demonstrated slower processing speed (with similar
accuracy) during the TMT-A and TMT-B, compared with
participants with fewer symptoms and healthy controls.
The hemodynamic pattern also demonstrated a clearly
distinguishable profile between patients with schizophrenia
and healthy controls. The differences were more marked in
those with higher symptom severity and when the complexity
of the cognitive task increased (i.e., TMT-B over TMT-A).
In summary, our results demonstrate a relationship between
psychopathological symptom load, cognitive demand, decreased
processing speed and distinct hemodynamic patterns in the
MCA during the TMT-A and TMT-B.
Healthy controls in our study demonstrate in both the TMT-
A and TMT-B, an initial increase in cerebral blood flow, which
returns smoothly to baseline values, thus reproducing previous
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TABLE 1 | Demographic and clinical characteristics of the sample.
Non- affected Mild-moderate Marked-severe
N = 15 N = 15 N = 15
Demographic Variables Statistics p
Age (in years) 33.87 (7.68) 34.05 (7.73) 32.40 (5.38) F (2, 42) = 0.222 0.80
Sex (male/female) 10/5 10/5 12/3 X2(2, 45) = 0.865 0.65
Education (in years) 19.17 (4.17)a 13.07 (2.60)a 13.10 (2.48)a F (2, 42) = 18.313 <0.001
Parents‘ Education (in years) 15.47 (3.83) 14.70 (3.00) 13.97 (3.03) F (2, 42) = 0.769 0.47
Clinical variables
BPRS – 30.27 (4.91)b 43.73 (3.67)b F (1, 28) = 72.421 <0.001
CGI-S – 3.60 (1.06)b 5.20 (0.68)b F (1, 28) = 24.436 <0.001
Chlorpromazine equivalent dosage (mg/d) 531.67 (165.69) 543.33 (176.14) F (1, 28) = 0.035 0.85
EPS – 3.47 (2.10) 4.93(7.91) F (1, 28) = 0.481 0.49
BAS – 0.53 (0.74) 1.07 (0.96) F (1, 28) = 2.89 0.10
Duration of illness (in years) – 8.67 (6.91) 12.20 (4.04) F (1, 28) = 2.922 0.09
Number of hospitalizations – 3.47 (2.03) 5.13 (4.70) F (1, 28) = 1.587 0.22
Cognitive performance
TMT-A (duration in seconds) 31.00 (7.43)c 40.20 (12.66)c 52.27 (30.84)c F (2, 42) = 4.388 0.019
TMT-B (duration in seconds) 66.20 (18.89)c 75.53 (22.98)c 111.13 (20.99)c F (2, 42) = 19.085 <0.001
Pairwise comparison: anon-affected > mild-moderate and marked-severe; bmarked-severe > mild-moderate: cmarked-severe < mild-moderate < non-affected.
FIGURE 1 | Bilateral Mean Flow Velocity changes from baseline in the Middle Cerebral Artery during the duration of the TMT-A (in seconds), according to
psychopathological symptom load [F (6, 1,792) = 17, p < 0.000].
findings in healthy subjects (38). Patients with schizophrenia
fail to reproduce this pattern. Firstly, the increase in MFV is
delayed; secondly, the MFV fails to return to baseline values.
The differences in the hemodynamic pattern for patients with
schizophrenia are accentuated, as psychopathological symptom
load and cognitive demand increases (i.e., TMT-B over TMT-
A). Processing speed may mediate the demonstrated differences
in hemodynamic pattern according to symptom severity and
cognitive demand for the TMT-A and TMT-B. This lends further
support to the notion that neuronal activity and cerebral blood
flow are closely coupled; with MFV resulting from the activation
of (or correspondingly the failure to deactivate) cortical areas in
the MCA’s irrigation territory (9, 12, 19, 39, 40). Patients with
schizophrenia demonstrate increased brain activity (as indicated
by a higher MFV) for lower performance (i.e., slower processing
speed) compared to healthy controls (16).
Frontiers in Psychiatry | www.frontiersin.org 5 June 2021 | Volume 12 | Article 679021
Egger et al. fTCD Symptom Load
FIGURE 2 | Bilateral Mean Flow Velocity changes from baseline in the Middle Cerebral Artery during the duration of the TMT-B (in seconds), according to
psychopathological symptom load [F (6, 2,692) = 61.93, p < 0.000].
Neuroimaging studies demonstrate different brain activation
patterns for the TMT-A and TMT-B. In the case of the
TMT-A, areas involved in graphomotor speed, visual scanning,
and selective attention are activated, whereas for the TMT-
B, activated areas relate to mental flexibility and executive
functioning (8). Previous findings also report a positive
correlation between the TMT-B and hemodynamic activity
in the MCA; this may be due to activation of the DLPFC,
temporal cortex, basal ganglia and the thalamus during the
TMT-B (17, 18). Several of these neuroanatomical areas are also
involved in psychopathology and the neurocognitive anomalies
related to schizophrenia (14, 41). Studies (including ours)
using fTCD demonstrate a correlation between performance
and hemodynamic patterns (14–16). This lends support to
the view that factors inherent to schizophrenia as well as to
other conditions characterized by executive dysfunction, such
as dysfunctional neuronal integrity, accelerated white matter
aging, hypoperfusion and increased vascular resistance (42–
45) may play a role. Since our sample was matched for age
and gender, we cannot make any inferences regarding the
effects of aging on our results. In the absence of a direct
anatomical image, taking into account that the irrigation territory
of the MCA is extensive, our findings in this respect are
not conclusive.
Our study has some other limitations which must be taken
into account in order to better understand and interpret
our findings. The lack of further neurocognitive assessments
limits our results to the cognitive abilities measured by the
TMTs. Taking into account that patients and healthy controls
showed similar error rates (i.e., both were accurate), the
main difference between the subsamples is processing speed.
Medication, particularly antipsychotics, can impair cognitive
performance, whether directly or through side effects (46–
50), Furthermore, they can also influence hemodynamics
(47). In our design, we did not directly control for this
potentially confounding factor. Nonetheless, we did not find a
difference regarding the dose and side effects of antipsychotics
among patients with schizophrenia. Those with a higher
psychopathological symptom load had a longer course of
the disease with higher rates of hospitalization, which may
be related to more severely impaired cognitive performance
(51, 52). The influence of systemic circulation on cerebral
blood flow, especially heart rate and arterial blood pressure,
is controlled for using a random motor activity (53, 54).
The control task aims to compensate for subtle alterations
in circulation and other confounding factors through relative
values compared to resting phase values before and after the
paradigm (53). Furthermore, all participants were medically
and neurologically stable, with no circulatory anomalies at the
time of the study. Other potential confounders, such as anxiety,
hypo- or hyperventilation (55), were not observed during the
measurement procedure.
In summary, patients with schizophrenia performed less
satisfactorily on both TMTs. Performance deteriorated with
increasing symptom load, parallel with a distinct cerebral blood
flow pattern in the MCA. Our results further support the view
that schizophrenia, particularly symptom load and thus severity,
influences performance in neurocognitive tasks, whilst being
related to distinct brain hemodynamic patterns. Furthermore,
these results support the use of fTCD as a brain imaging
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technique capable of studying brain hemodynamics during
neurocognitive tasks.
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